Risk of heparinoid use in cosmetics and moisturizers in individuals vaccinated against severe acute respiratory syndrome coronavirus 2

Kenji Yamamoto

doi:10.1186/s12959-021-00320-8

Risk of heparinoid use in cosmetics and moisturizers in individuals vaccinated against severe acute respiratory syndrome coronavirus 2

Thromb J. 2021 Sep 16;19(1):67. doi: 10.1186/s12959-021-00320-8.

Author

Kenji Yamamoto¹

Affiliation

¹ Department of Cardiovascular Surgery, Center of Varicose Veins, Okamura Memorial Hospital, 293-1 Kakita Shimizu-cho, Sunto-gun, Shizuoka, Japan. yamamoto@okamura.or.jp.

Abstract

Recently, heparin-induced thrombocytopenia (HIT) after vaccination with the vaccines manufactured by AstraZeneca and Pfizer-BioNTech has been published in the New England Journal of Medicine. These reports state that heparin was not used around the vaccination period in all cases. HIT after vaccination is more common in women; thus, heparinoid use can be suspected to induce HIT.

Keywords: COVID-19; coronavirus disease; heparin-induced thrombocytopenia; heparinoid; severe acute respiratory syndrome coronavirus 2; thromboembolism; vaccine.

Publication types

Letter